8-acetyl-7-benzyloxycoumarin | 65535-49-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 8-acetyl-7-benzyloxycoumarin
• 英文别名: 8-acetyl-7-(benzyloxy)-2H-chromen-2-one；8-acetyl-7-phenylmethoxychromen-2-one
• CAS: 65535-49-1
• 化学式: C₁₈H₁₄O₄
• 分子量: 294.307
• InChiKey: QMLSJCDSHGYBMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-acetyl-7-benzyloxycoumarin 在 palladium on activated charcoal 吡啶 、 sodium hydroxide 、 氢气 、 双氧水 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 30.33h， 生成 8-acetoxy-7-hydroxycoumarin
  参考文献：
  名称：

  First enantioselective synthesis of daphneticin and its regioisomer

  摘要：

  An enantioselective total synthesis of chiral daphneticin and its regioisomer is reported for the first time. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(02)00482-2
• 作为产物：
  描述：

  7-乙酰氧基香豆素 在 三氯化铝 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 26.0h， 生成 8-acetyl-7-benzyloxycoumarin
  参考文献：
  名称：

  First enantioselective synthesis of daphneticin and its regioisomer

  摘要：

  An enantioselective total synthesis of chiral daphneticin and its regioisomer is reported for the first time. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(02)00482-2

文献信息

• Methods for treating pathologies
  申请人：Omega Pharmaceutical, Inc.

  公开号：US20020002139A1

  公开（公告）日：2002-01-03

  The invention provides a method of modulating the immune system. Also provided is a method of treating a pathology associated with increased levels of a tumor necrosis factor. The invention further provides a method of treating a pathology resulting from infection by human immunodeficiency virus. Also provided is a method of treating chronic graft vs. host disease. Finally, the invention provides a method of promoting wound healing in a subject.

  本发明提供了一种调节免疫系统的方法。同时还提供了一种治疗与肿瘤坏死因子水平升高有关的病理的方法。本发明还提供了一种治疗人类免疫缺陷病毒感染引起的病理的方法。此外，本发明还提供了一种治疗慢性移植物抗宿主病的方法。最后，本发明提供了一种促进受试者伤口愈合的方法。
• 7,8-Disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range
  作者：Alfonso Maresca、Andrea Scozzafava、Claudiu T. Supuran

  DOI：10.1016/j.bmcl.2010.10.094

  日期：2010.12

  Two series of disubstituted coumarins incorporating ether and acetyl/propionyl moieties in positions 6,7- and 7,8- of the heterocyclic ring were synthesized investigated for the inhibition of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1). All these coumarins were very weak or ineffective as inhibitors of the housekeeping, offtarget isoforms CA I and II. The 6,7-disubstituted series showed ineffective inhibition also for the transmembrane tumor-associated isoforms CA IX and XII, whereas the corresponding isomeric 7,8-disubstituted coumarins showed nanomolar/subnanomolar inhibition of CA IX/XII. The nature and position of the groups substituting the coumarin ring in the 7,8-positions greatly influenced CA inhibitory properties, with C1-C4 alkyl ethers being the most effective inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
• Tanaka, Hitoshi; Ishihara, Masaya; Ichino, Kazuhiko, Heterocycles, 1987, vol. 26, # 12, p. 3115 - 3122
  作者：Tanaka, Hitoshi、Ishihara, Masaya、Ichino, Kazuhiko、Ito, Kazuo

  DOI：——

  日期：——
• TANAKA, HITOSHI;ISHIHARA, MASAYA;ICHINO, KAZUHIKO;ITO, KAZUO, HETEROCYCLES, 26,(1987) N 12, 3115-3122
  作者：TANAKA, HITOSHI、ISHIHARA, MASAYA、ICHINO, KAZUHIKO、ITO, KAZUO

  DOI：——

  日期：——
• [EN] METHODS FOR TREATING PATHOLOGIES<br/>[FR] PROCEDE DE TRAITEMENT DE PATHOLOGIES
  申请人：OMEGA PHARMACEUTICALS, INC.

  公开号：WO1994026282A1

  公开（公告）日：1994-11-24

  (EN) The invention provides a method of modulating the immune system. Also provided is a method of treating a pathology associated with increased levels of a tumor necrosis factor. The invention further provides a method of treating a pathology resulting from infection by human immunodeficiency virus. Also provided is a method of treating chronic graft vs. host disease. Finally, the invention provides a method of promoting wound healing in a subject.(FR) L'invention se rapporte à un procédé de modulation du système immunitaire, ainsi qu'à un procédé de traitement d'une pathologie associée à des niveaux accrus d'un facteur de nécrose tumorale. L'invention se rapporte en outre à un procédé de traitement d'une pathologie causée par une infection par le virus de l'immunodéficience humaine, ainsi qu'à un procédé de traitement de l'affection chronique du greffon contre l'hôte. Enfin, un procédé permettant de favoriser la cicatrisation des blessures chez un sujet est également décrit.